Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience-Reference-Cited by-同舟云学术

Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience

Published:2019-09-25 Issue:9 Volume:14 Page:e0223287
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Mangia Alessandra,Piazzolla Valeria,Giannelli Anna,Visaggi Egidio,Minerva Nicola,Palmieri Vincenzo,Carraturo Immacolata,Potenza Domenico,Napoli Nicola,Lauletta Gianfranco,Tagarielli Vincenzo,Santoro Rosanna,Piccigallo Ernesto,De Gioia Sergio,Chimenti Angelo,Cuccorese Giuseppe,Metrangolo Antonio,Mazzola Michele,Agostinacchio Ernesto,Mennea Giuseppe,Sabbà Carlo,Cela Marina,Copetti Massimiliano,Losappio Ruggiero

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference1 articles.

1. SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience;A Mangia;PLoS ONE,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending;Pathogens;2023-05-05

2. Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project;Journal of Clinical Medicine;2022-11-25

3. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy;PLOS ONE;2021-06-04

4. Analysis of hepatic stiffness after viral eradication in a population with chronic hepatitis C treated with DAAs;Medicina Clínica;2021-04

5. Analysis of hepatic stiffness after viral eradication in a population with chronic hepatitis C treated with DAAs;Medicina Clínica (English Edition);2021-04